London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for this. I've scheduled it to go out on my social media links. Not sure if anyone will even see it much less like it, but every little bit helps!
Ditto Matt, believe me it is.
I’ll second that.
Great news Chealsea, must be a big weight off your mind.
All the best. See you at that 2 pound party .
Thanks buddy, good to see you still around. Yep it is always the case,.....the next one, but I will allow myself to enjoy this one. You take care too.
Congratulations Chelsea on your 'clear' diagnosis, lets hope it stays like that mate. !
Thanks Ray, nope I will keep it schtum!!!
Oh well fell back asleep, missed the R NSs and it looks like they missed us too, lets have a look at how we are opening.
C7, great to hear about your good news.
Watch out for pick pockets in Naples and don't tell the Mafia about Scancell!
Tee Hee, well at least CH hasn"t used that word for a while, and he has earned a lot of respect from me for what I presume is his excellent work with the three collaborations on the Third Platform, amongst with what I can only presume are many other issues too.
I"ve got some really good news regarding my scans last Monday which were the first ones I have had since June last year after the Cryoblation operation, and after going to the Radiographer for a Stewards Enquiry, it has come back ""clear". The first time in seven years I have been clear for so long. The rest of me,....well no need to go there, but i have booked to go to Naples in November for just under a week with friends, not quite the world cruise I once had my eyes on, but the first time I have been away for nigh on ten years.
So come on Scancell, you have a timeline from me, lets get our patients treated and get those collaborations over the line, by end of this year
As for us. we know what we are waiting for, careful what you wish for springs to mind, but lets get an update, filled with hope , I think we all deserve that.
Let's hope it is not a CH "shortly"
I just wonder how long ""shortly"" is in Biotech terms, lol, well we should find out in the update with the Interims.
Good to see Lindy getting the Market to receive MOD1 warmly, and I just wonder how long we will have to wait for our fourth collaboration?? It feels like that could be anytime soon, and it is certainly supporting the SP as we wait on so many items of news, the rises are getting more, the retraces smaller, and remember momentum was driven by the Vulpes Holding RNS on the third platform on collaboration two, and the third collaboration we saw the 8p breached, and a record in recent times with 60 trades in a`day. So that is collaborations in Sept, December and January, the next one, the fourth may not be far away at all.
Till tomorrow guys, still fair to say news will come this week with the Interims/Updates, even next Monday at a push a day before the February 4th Conference. A reasonable bet too that news of a Fourth Collaboration could come at any stage, each one validating the potential of the previous one, not just for us PIs but for the Industries information too
Just update on AIM share chat.and delighted to see three likes on the main post and another on the second smaller one, not bad, it was only posted a couple of hours ago and thanks to those here who are supporting it. One thing I promise is many more PIS are aware of our potential than they were just a couple of months back, lets keep it going.
Nice one cc, that is two conferences you have uncovered in the last couple of days, to add to the Feb 4th one, just a clip.........
FEATURED PRESENTATION: Stress-Induced Post-Translational Modifications (siPTMs) as Targets for Cancer Vaccines
Lindy Durrant, Ph.D., Professor of Cancer Immunotherapy, University of Nottingham; CSO, Scancell Ltd.
Citrullination is a widely expressed, novel, stress-induced post-translational modification that is a potent target for cancer vaccines. There is a repertoire of cytotoxic CD4 T cells in mice and humans that recognizes citrullinated epitopes. Tumors over-express PAD enzymes. Inflammation and stress induce high levels of autophagy and MHC-II presentation of citrullinated epitopes on tumors. Citrullinated peptides demonstrate potent anti-tumor immunity with no associated toxicity and will shortly enter the clinic.
So, "" Citrullinated peptides demonstrate potent anti-tumor immunity with no associated toxicity and will shortly enter the clinic."", we can almost feel Moditope coming
Nice mention in the ADC review of Lindy's presentation at the 5th annual- immuno oncology summit 9th - 12th March 2020.
https://www.adcreview.com/conference-coverage/next-generation-immunotherapies/